[Electrophysiologic and hemodynamic effects of the new anti-arrhythmia agent diprafenone]
- PMID: 3673162
[Electrophysiologic and hemodynamic effects of the new anti-arrhythmia agent diprafenone]
Abstract
Diprafenone is a new antiarrhythmic agent currently under clinical investigation, with close chemical similarity to propafenone. In this study, the electrophysiological and haemodynamic effects of the compound were investigated both in animals, by experiment, and in man. Diprafenone produces a dose-dependent prolongation of conduction in all parts of the conducting system. Lengthening of PQ-time is more pronounced than prolongation of QRS. The atrial and ventricular refractory periods are also significantly prolonged. There are no significant changes in the QT-time. Heart rate and aortic pressure are slightly decreased. The electrophysiological and haemodynamic profile of Diprafenone is similar to propafenone with respect to a dominant local anaesthetic activity and an additional beta-sympatholytic effect. However, with respect to the dose needed, the efficacy of the new drug appears to be significantly stronger. Diprafenone can be considered an effective antiarrhythmic drug for the treatment of supraventricular and ventricular tachyarrhythmias.
Similar articles
-
Assessment of the antiarrhythmic profile of the new class I agent diprafenone.Arzneimittelforschung. 1985;35(9):1387-93. Arzneimittelforschung. 1985. PMID: 4084340
-
[Diprafenone--comparative study of anti-arrhythmia therapy with propafenone].Z Kardiol. 1988 Jul;77(7):464-9. Z Kardiol. 1988. PMID: 2463720 Clinical Trial. German.
-
Assessment of the electrophysiologic, antiarrhythmic and haemodynamic profile of a new isoquinolinedione derivative.Arzneimittelforschung. 1987 Aug;37(8):917-9. Arzneimittelforschung. 1987. PMID: 3675686
-
Restacorin, a new antiarrhythmic drug: a review of its electrophysiologic and hemodynamic properties.Int J Clin Pharmacol Ther. 1994 Jun;32(6):278-81. Int J Clin Pharmacol Ther. 1994. PMID: 7921525 Review.
-
A summary of the acute effects of falipamil in man.Eur Heart J. 1987 Dec;8 Suppl L:141-6. doi: 10.1093/eurheartj/8.suppl_l.141. Eur Heart J. 1987. PMID: 3330525 Review.
Cited by
-
Evaluation of the beta-adrenoceptor blocking activity of the Class Ic antiarrhythmic drug diprafenone in man.Eur J Clin Pharmacol. 1989;36(6):579-82. doi: 10.1007/BF00637739. Eur J Clin Pharmacol. 1989. PMID: 2570700 Clinical Trial.